Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 15/20 | 0.60 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.60 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.59 |
| ▸ | S1PR2 | O95136 | 7/20 | 0.57 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13078669 | 0.83 | SLC9A1 (0.63) | S1PR4S1PR5SLC9A1S1PR2S1PR3 | |
| SCHEMBL13044122 | 0.82 | MEN1 (0.53) | S1PR4S1PR5SLC9A1S1PR2S1PR3 | |
| SCHEMBL12670456 | 0.81 | ALDH1A1 (0.68) | S1PR4S1PR5SLC9A1S1PR2S1PR3 | |
| SCHEMBL4946520 | 0.81 | S1PR4 (0.62) | S1PR4S1PR5SLC9A1S1PR2S1PR3 | |
| SCHEMBL15218327 | 0.80 | SLC9A1 (0.72) | S1PR4S1PR5SLC9A1S1PR2S1PR3 | |
| SCHEMBL13044091 | 0.78 | ALDH1A1 (0.59) | SLC9A1LMNAMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL13809597 | 0.76 | S1PR4 (0.52) | S1PR4S1PR5SLC9A1S1PR2S1PR3 | |
| SCHEMBL4946325 | 0.74 | SLC9A1 (1.00) | SLC9A1 | |
| SCHEMBL4946319 | 0.72 | SLC9A1 (0.61) | S1PR4S1PR5SLC9A1S1PR2S1PR3 | |
| SCHEMBL8168081 | 0.72 | ALDH1A1 (0.59) | LMNAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829571-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090124668-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-14 | — | — | US | disclosed |
| US-7482335-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| US-20070032526-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CARTER PEROY H | 2007-02-08 | — | — | US | disclosed |
| US-7163937-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
| US-7163937-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032526-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | S1PR4 51/4885S1PR5 41/4885SLC9A1 773/4885 |
| US-20090124668-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCL11, CCL2, CCR1 | S1PR4 51/4885S1PR5 41/4885SLC9A1 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.